| For: | Lam R, Lim JK. Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents. World J Hepatol 2024; 16(3): 331-343 [PMID: 38577537 DOI: 10.4254/wjh.v16.i3.331] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v16/i3/331.htm |
| Number | Citing Articles |
| 1 |
Ramakrishnamraju Samunuri, Masaaki Toyama, Mohan Kasula, Ashok Kumar Jha, Mika Okamoto, Masanori Baba, Ashoke Sharon. Synthesis, Cytotoxicity, and Mechanistic Evaluation of 7‐Deazapurine‐Based Neplanocin Analogues as Selective Anti‐HBV Agents. ChemistrySelect 2025; 10(22) doi: 10.1002/slct.202500784
|
| 2 |
Bai-Hua Zhang, Yuanping Zhou, Stephen Horrigan, Laura Luckenbaugh, Jianming Hu, Fabien Zoulim, Yong-Yuan Zhang. HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination. Molecular Therapy Methods & Clinical Development 2025; 33(4): 101646 doi: 10.1016/j.omtm.2025.101646
|
| 3 |
Chiara Rubino, Mariangela Stinco, Giuseppe Indolfi. Hepatitis co-infection in paediatric HIV: progressing treatment and prevention. Current Opinion in HIV and AIDS 2024; 19(6): 338 doi: 10.1097/COH.0000000000000882
|
| 4 |
Javiera Cortés‐Ríos, Tianjing Ren, Nathan Hanan, Anna Sher, Ahmed Nader, Mindy Magee, William J. Jusko, Rajat Desikan. Hepatitis B In Silico Trials Capture Functional Cure, Indicate Mechanistic Pathways, and Suggest Prognostic Biomarker Signatures. Clinical Pharmacology & Therapeutics 2025; 118(3): 600 doi: 10.1002/cpt.3718
|
| 5 |
Simon P. Fletcher, Rudolf K. Beran. Understanding and Targeting HBV Transcription and Post-Transcriptional Regulation. Viruses 2024; 16(11): 1793 doi: 10.3390/v16111793
|
| 6 |
Juntian Yao, Jinsheng Guo, Youhua Xie. Hepatitis B virus induced cirrhosis and hepatocarcinoma: pathogenesis and therapeutics. Exploration of Digestive Diseases 2025; doi: 10.37349/edd.2025.100565
|
